Corcept Therapeutics Incorporated

NasdaqCM:CORT Stock Report

Market Cap: US$8.0b

Corcept Therapeutics Valuation

Is CORT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CORT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$70.35
Fair Value
8.2% overvalued intrinsic discount
4
Number of Analysts

Below Fair Value: CORT ($76.09) is trading above our estimate of fair value ($70.35)

Significantly Below Fair Value: CORT is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CORT?

Key metric: As CORT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CORT. This is calculated by dividing CORT's market cap by their current earnings.
What is CORT's PE Ratio?
PE Ratio60.9x
EarningsUS$132.51m
Market CapUS$8.04b

Price to Earnings Ratio vs Peers

How does CORT's PE Ratio compare to its peers?

The above table shows the PE ratio for CORT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.7x
JAZZ Jazz Pharmaceuticals
13.8x32.07%US$6.7b
ELAN Elanco Animal Health
16.9x-2.63%US$6.3b
PBH Prestige Consumer Healthcare
19.6x4.44%US$4.2b
RPRX Royalty Pharma
12.5x5.77%US$18.5b
CORT Corcept Therapeutics
60.9x42.23%US$8.0b

Price-To-Earnings vs Peers: CORT is expensive based on its Price-To-Earnings Ratio (60.9x) compared to the peer average (15.7x).

Price to Earnings Ratio vs Industry

How does CORT's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.3xn/aUS$1.63b
CPMD CannaPharmaRX
2.9xn/aUS$3.61m
CNNC Cannonau
0.3xn/aUS$96.73k
SEEL.Q Seelos Therapeutics
0.0002xn/aUS$681.00
CORT 60.9xIndustry Avg. 17.3xNo. of Companies5PE01224364860+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CORT is expensive based on its Price-To-Earnings Ratio (60.9x) compared to the US Pharmaceuticals industry average (17.3x).

Price to Earnings Ratio vs Fair Ratio

What is CORT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CORT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio60.9x
Fair PE Ratio71.6x

Price-To-Earnings vs Fair Ratio: CORT is good value based on its Price-To-Earnings Ratio (60.9x) compared to the estimated Fair Price-To-Earnings Ratio (71.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CORT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$76.09
US$138.25
+81.69%
4.01%US$145.00US$131.00n/a4
May ’26US$71.48
US$143.25
+100.41%
5.44%US$150.00US$131.00n/a4
Apr ’26US$91.93
US$142.50
+55.01%
6.31%US$150.00US$128.00n/a4
Mar ’26US$60.58
US$99.75
+64.66%
23.43%US$130.00US$76.00n/a4
Feb ’26US$66.92
US$88.25
+31.87%
27.83%US$130.00US$67.00n/a4
Jan ’26US$50.39
US$74.90
+48.64%
6.01%US$80.00US$67.00n/a5
Dec ’25US$57.68
US$74.90
+29.85%
6.01%US$80.00US$67.00n/a5
Nov ’25US$47.62
US$74.90
+57.29%
6.01%US$80.00US$67.00n/a5
Oct ’25US$46.75
US$67.60
+44.60%
17.62%US$78.00US$45.00n/a5
Sep ’25US$35.30
US$59.60
+68.84%
26.01%US$78.00US$38.00n/a5
Aug ’25US$37.94
US$59.60
+57.09%
26.01%US$78.00US$38.00n/a5
Jul ’25US$32.67
US$49.70
+52.13%
30.03%US$70.50US$35.00n/a5
Jun ’25US$30.17
US$45.50
+50.81%
28.21%US$70.50US$35.00n/a5
May ’25US$23.88
US$42.80
+79.23%
21.89%US$61.00US$35.00US$71.485
Apr ’25US$25.74
US$42.80
+66.28%
21.89%US$61.00US$35.00US$91.935
Mar ’25US$24.06
US$42.80
+77.89%
21.89%US$61.00US$35.00US$60.585
Feb ’25US$21.63
US$36.83
+70.29%
32.48%US$61.00US$23.00US$66.926
Jan ’25US$32.48
US$37.00
+13.92%
18.59%US$50.00US$27.00US$50.396
Dec ’24US$25.97
US$36.83
+41.83%
18.64%US$50.00US$27.00US$57.686
Nov ’24US$28.09
US$34.08
+21.34%
19.94%US$47.50US$26.00US$47.626
Oct ’24US$27.25
US$33.42
+22.65%
20.56%US$47.50US$26.00US$46.756
Sep ’24US$33.10
US$33.42
+0.96%
20.56%US$47.50US$26.00US$35.306
Aug ’24US$25.00
US$30.67
+22.67%
20.94%US$44.00US$25.00US$37.946
Jul ’24US$22.25
US$30.67
+37.83%
20.94%US$44.00US$25.00US$32.676
Jun ’24US$22.97
US$30.67
+33.51%
20.94%US$44.00US$25.00US$30.176
May ’24US$22.77
US$29.43
+29.24%
23.53%US$44.00US$20.00US$23.887
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
US$138.25
Fair Value
45.0% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 04:10
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corcept Therapeutics Incorporated is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
David BuckB. Riley Securities, Inc.
Edward NashCanaccord Genuity